KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Payables (2016 - 2025)

Rigel Pharmaceuticals has reported Payables over the past 16 years, most recently at $7.2 million for Q4 2025.

  • For Q4 2025, Payables rose 115.36% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $7.2 million, up 115.36%, while the annual FY2025 figure was $7.2 million, 115.36% up from the prior year.
  • Payables for Q4 2025 was $7.2 million at Rigel Pharmaceuticals, up from $3.8 million in the prior quarter.
  • Over five years, Payables peaked at $15.0 million in Q4 2022 and troughed at $1.7 million in Q2 2021.
  • A 5-year average of $5.5 million and a median of $4.9 million in 2021 define the central range for Payables.
  • Biggest five-year swings in Payables: skyrocketed 295.26% in 2022 and later plummeted 57.37% in 2025.
  • Year by year, Payables stood at $3.8 million in 2021, then skyrocketed by 295.26% to $15.0 million in 2022, then crashed by 52.39% to $7.1 million in 2023, then crashed by 53.25% to $3.3 million in 2024, then surged by 115.36% to $7.2 million in 2025.
  • Business Quant data shows Payables for RIGL at $7.2 million in Q4 2025, $3.8 million in Q3 2025, and $7.3 million in Q2 2025.